Influenza Vaccine Market (By Vaccine Type; By Indication; By Age Group; By Route Of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Influenza Vaccine Market 

5.1. COVID-19 Landscape: Influenza Vaccine Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Influenza Vaccine Market, By Vaccine type

8.1. Influenza Vaccine Market, by Vaccine type, 2022-2030

8.1.1. Inactivated

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Live Attenuated

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Influenza Vaccine Market, By Indication

9.1. Influenza Vaccine Market, by Indication, 2022-2030

9.1.1. Quadrivalent

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Trivalent

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Influenza Vaccine Market, By Age group 

10.1. Influenza Vaccine Market, by Age group, 2022-2030

10.1.1. Paediatric

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Adult

10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Influenza Vaccine Market, By Route of Administration

11.1. Influenza Vaccine Market, by Route of Administration, 2022-2030

11.1.1. Injection

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Nasal Spray

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Influenza Vaccine Market, By Distribution channel

12.1. Influenza Vaccine Market, by Distribution channel, 2022-2030

12.1.1. Hospitals & Pharmacy

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Government & Institutional supply

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Other

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Influenza Vaccine Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.1.2. Market Revenue and Forecast, by Indication (2017-2030)

13.1.3. Market Revenue and Forecast, by Age group (2017-2030)

13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Indication (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Age group (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.7. Market Revenue and Forecast, by Distribution channel (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Indication (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Age group (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.2.2. Market Revenue and Forecast, by Indication (2017-2030)

13.2.3. Market Revenue and Forecast, by Age group (2017-2030)

13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.5. Market Revenue and Forecast, by Distribution channel (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Indication (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Age group (2017-2030)

13.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.8. Market Revenue and Forecast, by Distribution channel (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Indication (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Age group (2017-2030)

13.2.10. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.11. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Indication (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Age group (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.13. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Indication (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Age group (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.15. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.3.2. Market Revenue and Forecast, by Indication (2017-2030)

13.3.3. Market Revenue and Forecast, by Age group (2017-2030)

13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Indication (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Age group (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.7. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Indication (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Age group (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.9. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Indication (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Age group (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Indication (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Age group (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.4.2. Market Revenue and Forecast, by Indication (2017-2030)

13.4.3. Market Revenue and Forecast, by Age group (2017-2030)

13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Indication (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Age group (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.7. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Indication (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Age group (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.9. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Indication (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Age group (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Indication (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Age group (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.5.2. Market Revenue and Forecast, by Indication (2017-2030)

13.5.3. Market Revenue and Forecast, by Age group (2017-2030)

13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Indication (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Age group (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.7. Market Revenue and Forecast, by Distribution channel (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Vaccine type (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Indication (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Age group (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Distribution channel (2017-2030)

Chapter 14. Company Profiles

14.1. GlaxoSmithKline Plc

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Biodiem

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Sanofi

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. AstraZeneca

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. CSL Limited

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Emergent Biosolutions

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. BIKEN Co, Ltd.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. F. Hoffmann-La Roche Ltd.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Abbott Laboratories

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Merck & Co., Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms